ERS 2026: GB-0895 clinical results show potential of next-gen anti-TSLP for asthma - Pharmaceutical Technology

At ERS 2026, Generate: Biomedicines investigators presented pharmacodynamics and safety results from the company’s ongoing Phase I study (NCT07116889) evaluating GB-0895. As a lymphocyte-stimulating cytokine, TSLP has been shown to drive the inflammatory response in the airways of patients with severe asthma. Credit: mi_viri via Shutterstock.com. Unlock FREE Access to Premium Content ​Discover exclusive forecasts, analyst insights, and in-depth pharmaceutical industry analysis spanning drug development, manufacturing, regulation, and global healthcare trends. With a free Pharmaceutical Technology profile, you can: The leading site for news and procurement in the pharmaceutical industry

Source: Pharmaceutical Technology